Dopamine receptor antagonists block nerve growth factor-induced hyperactivity

European Journal of Pharmacology

Volumn 326, Issue 1, 1997, Pages 1-5

  Kobayashi, Satoshi ^a   Ögren, Sven Ove ^a   Ebendal, Ted ^b   Olson, Lars ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Acetylcholine; Dopamine receptor antagonist; Locomotion; NGF (nerve growth factor); Nicotinic receptor

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; NERVE GROWTH FACTOR; RACLOPRIDE; RECEPTOR SUBTYPE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; HYPERACTIVITY; LOCOMOTION; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031011261     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)83487-5     Document Type: Article

References (25)

1. Amt, J., Hyttel, J., Perregaard, J., 1987. Dopamine D-1 receptor agonists combined with the selective D-2 agonist quinpirole facilitate the expression of oral stereotyped behaviour in rats. Eur. J. Pharmacol. 133, 137-145.
2. Asher, I.M., Aghajanian, G.K., 1974. 6-Hydroxydopamine lesions of olfactory tubercles and caudate nuclei: behavior in rats. Brain Res. 82, 1-12.
3. Clarke, P.B.S., Pert, A., 1985. Autoradiographic evidence for nicotinic receptors on nigrostriatal and mesolimbic dopaminergic neurons. Brain Res. 348, 355-358.
4. Clarke, P.B.S., Fu, D.S., Jakubovic, A., Fibiger, H.C., 1988. Evidence that mesolimbic dopaminergic activation underlies the locomotor stimulant action of nicotine in rats. J. Pharmacol. Exp. Ther. 246, 701-708.
5. Damaj, M.I., Martin, B.R., 1993. Is the dopaminergic system involved in the central effects of nicotine in mice?. Psychopharmacology 111, 106-108.
6. Ebendal, T., 1989. NGF in CNS: experimental data and clinical implications. Prog. Growth Factor Res. 1, 143-159.
7. Ebendal, T., 1992. Function and evolution in the NGF family and its receptors. J. Neurosci. Res. 32, 461-470.
8. Ebendal, T., Olson, L., Seiger, Å., Belew, M., 1984. Nerve growth factors in chick and rat tissues. In: Black, I. (Ed.), Cellular and Molecular Biology of Neuronal Development. Plenum Press, New York, NY, pp. 231-242.
9. Fischer, W., Wictorin, K., Björklund, A., Williams, L.R., Varon, S., Gage, F.H., 1987. Amelioration of cholinergic atrophy and spatial memory impairment in aged rats by nerve growth factor. Nature 329, 65-68.
10. Kebabian, J.W., Calne, D.B., 1979. Multiple receptors for dopamine. Nature 277, 93-96.
11. Kelly, P.H., Seviour, P.W., Iversen, S.D., 1975. Amphetamine and apomorphine responses in the rat following 6-OHDA lesions of the nucleus accumbens septi and corpus striatum. Brain Res. 94, 507-522.
12. Knipper, M., Berzaghi, M.P., Blöchl, A., Breer, H., Thoenen, H., Lindholm, D., 1994. Positive feedback between acetylcholine and the neurotrophins nerve growth factor and brain-derived neurotrophic factor in the rat hippocampus. Eur. J. Neurosci. 6, 668-671.
13. Kobayashi, S., Ögren, S.O., Ebendal, T., Olson, L., 1997. Intraventricular injection of NGF, but not BNDF, induces rapid motor activation that is inhibited by nicotinic receptor antagonists. Exp. Brain Res., in press.
14. Levi, A., Alema, S., 1991. The mechanism of action of nerve growth factor. Annu. Rev. Pharmacol. Toxicol. 31, 205-228.
15. Mobley, W., Schenker, A., Shooter, E., 1976. Characterization and isolation of proteolytically modified nerve growth factor. Biochemistry 15, 5543-5552.
16. Nisell, M., Nomikos, G.G., Svensson, T.H., 1994. Systemic nicotine-induced dopamine release in the rat nucleus accumbens is regulated by nicotinic receptors in the ventral tegmental area. Synapse 16, 36-44.
17. O'Neill, M.F., Dourish, C.T., Iversen, S.D., 1991. Evidence for an involvement of D1 and D2 dopamine receptors in mediating nicotine-induced hyperactivity in rats. Psychopharmacology 104, 343-350.
18. Ögren, S.O., Köhler, C., Fuxe, K., Ängeby, K., 1979. Behavioral effects of ergot drugs. In: Fuxe, K., Calne, B.D. (Eds.), Dopaminergic Ergot Derivates and Motor Function. Pergamon Press, Oxford, pp. 187-205.
19. 2 receptor antagonist raclopride discriminates between dopamine-mediated motor functions. Psychopharmacology 90, 287-294.
20. Palmer, M.R., Eriksdotter-Nilsson, M., Henschen, A., Ebendal, T., Olson, L., 1993. Nerve growth factor-induced excitation of selected neurons in the brain which is blocked by a low-affinity receptor antibody. Exp. Brain Res. 93, 226-230.
21. Pitchford, S., Moor, K.D., Glaeser, B.S., 1995. Nerve growth factor stimulates rapid metabolic responses in PC12 cells. Am. J. Physiol. 268, C936-C943.
22. Reavill, C., Stolerman, I.P., 1990. Locomotor activity in rats after administration of nicotinic agonists intracerebrally. Br. J. Pharmacol. 99, 273-278.
23. Schwartz, R.D., Lehmann, J., Kellar, K.J., 1984. Presynaptic nicotinic cholinergic receptors labeled by H-acetylcholine on catecholamine and serotonin axons in brain. J. Neurochem. 42, 1495-1498.
24. Starr, M.S., Starr, B.S., 1989. Behavioural synergism between the dopamine agonists SKF 38393 and LY 171555 in dopamine-depleted mice: antagonism by sulpiride reveals only stimulant postsynaptic D-2 receptors. Pharmacol. Biochem. Behav. 33, 41-44.
25. Wonnacott, S., Drasdo, A., Sanderson, E., Rowell, P., 1990. Presynaptic nicotinic receptors and the modulation of transmitter release. In: Bock, G., Marsh, J. (Eds.), The Biology of Nicotine Dependence. John Wiley and Sons, Chichester, pp. 87-105.